Prevalence and correlates of stocking up on drugs during the COVID-19 pandemic: Data from the C3PNO Consortium.
COVID-19
Overdose
Risky drug use
Stockpiling drugs
Substance use
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
06
12
2021
revised:
03
10
2022
accepted:
03
10
2022
pubmed:
21
10
2022
medline:
15
12
2022
entrez:
20
10
2022
Statut:
ppublish
Résumé
Data from the COVID-19 pandemic describes increases in drug use and related harms, especially fatal overdose. However, evidence is needed to better understand the pathways from pandemic-related factors to substance use behaviours. Thus, we investigated stockpiling drugs among people who use drugs (PWUD) in five cities in the United States and Canada. We used data from two waves of interviews among participants in nine prospective cohorts to estimate the prevalence and correlates of stockpiling drugs in the previous month. Longitudinal correlates were identified using bivariate and multivariate generalized linear mixed-effects modeling analyses. From May 2020 to February 2021, we recruited 1873 individuals who completed 2242 interviews, of whom 217 (11.6%) reported stockpiling drugs in the last month at baseline. In the multivariate model, stockpiling drugs was significantly and positively associated with reporting being greatly impacted by COVID-19 (Adjusted Odds Ratio [AOR]= 1.21, 95% CI: 1.09-1.45), and at least daily use of methamphetamine (AOR = 4.67, 95% CI: 2.75-7.94) in the past month. We observed that approximately one-in-ten participants reported stocking up on drugs during the COVID-19 pandemic. This behaviour was associated with important drug-related risk factors including high-intensity methamphetamine use. While these correlations need further inquiry, it is possible that addressing the impact of COVID-19 on vulnerable PWUD could help limit drug stockpiling, which may lower rates of high-intensity stimulant use.
Sections du résumé
BACKGROUND
BACKGROUND
Data from the COVID-19 pandemic describes increases in drug use and related harms, especially fatal overdose. However, evidence is needed to better understand the pathways from pandemic-related factors to substance use behaviours. Thus, we investigated stockpiling drugs among people who use drugs (PWUD) in five cities in the United States and Canada.
METHODS
METHODS
We used data from two waves of interviews among participants in nine prospective cohorts to estimate the prevalence and correlates of stockpiling drugs in the previous month. Longitudinal correlates were identified using bivariate and multivariate generalized linear mixed-effects modeling analyses.
RESULTS
RESULTS
From May 2020 to February 2021, we recruited 1873 individuals who completed 2242 interviews, of whom 217 (11.6%) reported stockpiling drugs in the last month at baseline. In the multivariate model, stockpiling drugs was significantly and positively associated with reporting being greatly impacted by COVID-19 (Adjusted Odds Ratio [AOR]= 1.21, 95% CI: 1.09-1.45), and at least daily use of methamphetamine (AOR = 4.67, 95% CI: 2.75-7.94) in the past month.
CONCLUSIONS
CONCLUSIONS
We observed that approximately one-in-ten participants reported stocking up on drugs during the COVID-19 pandemic. This behaviour was associated with important drug-related risk factors including high-intensity methamphetamine use. While these correlations need further inquiry, it is possible that addressing the impact of COVID-19 on vulnerable PWUD could help limit drug stockpiling, which may lower rates of high-intensity stimulant use.
Identifiants
pubmed: 36266158
pii: S0376-8716(22)00391-X
doi: 10.1016/j.drugalcdep.2022.109654
pmc: PMC9535877
pii:
doi:
Substances chimiques
Methamphetamine
44RAL3456C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109654Subventions
Organisme : NIDA NIH HHS
ID : U01 DA036297
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036926
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA038886
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA021525
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA053136
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest M-JM holds the Canopy Growth professorship in cannabis science at the University of British Columbia, a position established through arm’s length gifts to the university from Canopy Growth, a licensed producer of cannabis, and the Government of British Columbia’s Ministry of Mental Health and Addictions. He has no financial relationships with the cannabis industry.
Références
Front Psychiatry. 2020 Oct 23;11:584462
pubmed: 33192730
J Ethnopharmacol. 1981 Mar-May;3(2-3):353-66
pubmed: 7242115
Drug Alcohol Rev. 2020 May;39(4):297-300
pubmed: 32445265
Int J Epidemiol. 2021 Mar 3;50(1):31-40
pubmed: 33682886
JAMA Netw Open. 2020 Sep 1;3(9):e2022942
pubmed: 32990735
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
BJPsych Open. 2020 Oct 19;6(6):e125
pubmed: 33070797
Am J Epidemiol. 2016 May 1;183(9):852-60
pubmed: 27049004
Front Psychiatry. 2021 Aug 06;12:646206
pubmed: 34421664
J Addict Med. 2020 Dec;14(6):e287-e289
pubmed: 33009167
J Int AIDS Soc. 2020 Jul;23(7):e25583
pubmed: 32697423
Subst Abus. 2018;39(3):384-389
pubmed: 29432084
Trends Pharmacol Sci. 2004 Apr;25(4):210-8
pubmed: 15063085
J Anal Toxicol. 1995 Oct;19(6):459-78
pubmed: 8926741
JAMA. 2017 Dec 19;318(23):2295-2296
pubmed: 29049472
Behav Pharmacol. 2014 Sep;25(5-6):473-92
pubmed: 25083570